GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexicon Pharmaceuticals Inc (NAS:LXRX) » Definitions » Shiller PE Ratio

Lexicon Pharmaceuticals (Lexicon Pharmaceuticals) Shiller PE Ratio : (As of Apr. 28, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Lexicon Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Lexicon Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Lexicon Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexicon Pharmaceuticals Shiller PE Ratio Chart

Lexicon Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Lexicon Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Lexicon Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Lexicon Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lexicon Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lexicon Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Lexicon Pharmaceuticals's Shiller PE Ratio falls into.



Lexicon Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Lexicon Pharmaceuticals's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Lexicon Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.2/129.4194*129.4194
=-0.200

Current CPI (Dec. 2023) = 129.4194.

Lexicon Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.420 99.695 -0.545
201406 -0.350 100.560 -0.450
201409 -0.550 100.428 -0.709
201412 -0.035 99.070 -0.046
201503 -0.270 99.621 -0.351
201506 -0.270 100.684 -0.347
201509 -0.340 100.392 -0.438
201512 0.760 99.792 0.986
201603 -0.340 100.470 -0.438
201606 -0.370 101.688 -0.471
201609 -0.350 101.861 -0.445
201612 -0.310 101.863 -0.394
201703 -0.330 102.862 -0.415
201706 -0.330 103.349 -0.413
201709 -0.290 104.136 -0.360
201712 -0.270 104.011 -0.336
201803 -0.400 105.290 -0.492
201806 -0.330 106.317 -0.402
201809 -0.260 106.507 -0.316
201812 -0.160 105.998 -0.195
201903 -0.210 107.251 -0.253
201906 -0.220 108.070 -0.263
201909 1.950 108.329 2.330
201912 -0.480 108.420 -0.573
202003 -0.630 108.902 -0.749
202006 -0.650 108.767 -0.773
202009 0.710 109.815 0.837
202012 -0.040 109.897 -0.047
202103 -0.150 111.754 -0.174
202106 -0.130 114.631 -0.147
202109 -0.160 115.734 -0.179
202112 -0.170 117.630 -0.187
202203 -0.160 121.301 -0.171
202206 -0.160 125.017 -0.166
202209 -0.130 125.227 -0.134
202212 -0.160 125.222 -0.165
202303 -0.170 127.348 -0.173
202306 -0.220 128.729 -0.221
202309 -0.210 129.860 -0.209
202312 -0.200 129.419 -0.200

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Lexicon Pharmaceuticals  (NAS:LXRX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Lexicon Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Lexicon Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Lexicon Pharmaceuticals (Lexicon Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
2445 Technology Forest Boulevard, 11th Floor, The Woodlands, TX, USA, 77381
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
Executives
Philippe Amouyal director C/O CAVA GROUP, INC., 14 RIDGE SQUARE NW, SUITE 500, WASHINGTON DC 20016
Lonnel Coats director, officer: President and CEO 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Raymond Debbane director, 10 percent owner C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, NEW YORK NY 10022
Thomas Garner officer: SVP, Chief Commercial Officer 2445 TECHNOLOGY FOREST BLVD, 11TH FLOOR, SPRING TX 77381
Jeffrey L Wade officer: EVP, Gen. Counsel 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Wendy Mcdermott officer: VP, Human Resources 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381
Diane E. Sullivan director C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60
Artal International S.c.a. director, 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Invus Partners, Llc director, 10 percent owner 750 LEXINGTON AVE, 30TH FL, NEW YORK NY 10022
Ulys, Llc director, 10 percent owner C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022
Kiernan Seth officer: VP, Chief Commercial Officer 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381
Kenneth B. Kassler-taub officer: SVP, Regulatory & QA 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381
Kristen Alexander officer: VP, Finance and Accounting 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS TX 77381
Craig B Granowitz officer: SVP, Chief Medical Officer 58 CHESTNUT STREET, UNIT #3, MORRISTOWN NJ 07960
James F Tessmer officer: VP, Finance & Acctg 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381